- Home
- OLP vs MLYS Comparison
OLP vs MLYS Comparison
Compare OLP & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OLP
- MLYS
- Stock Information
- Founded
- OLP 1982
- MLYS 2019
- Country
- OLP United States
- MLYS United States
- Employees
- OLP N/A
- MLYS N/A
- Industry
- OLP Real Estate Investment Trusts
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- OLP Real Estate
- MLYS Health Care
- Exchange
- OLP Nasdaq
- MLYS Nasdaq
- Market Cap
- OLP 483.3M
- MLYS 890.6M
- IPO Year
- OLP N/A
- MLYS 2023
- Fundamental
- Price
- OLP $22.96
- MLYS $37.29
- Analyst Decision
- OLP
- MLYS Strong Buy
- Analyst Count
- OLP 0
- MLYS 6
- Target Price
- OLP N/A
- MLYS $42.60
- AVG Volume (30 Days)
- OLP 58.8K
- MLYS 2.6M
- Earning Date
- OLP 11-04-2025
- MLYS 11-10-2025
- Dividend Yield
- OLP 7.82%
- MLYS N/A
- EPS Growth
- OLP N/A
- MLYS N/A
- EPS
- OLP 1.29
- MLYS N/A
- Revenue
- OLP $94,839,000.00
- MLYS N/A
- Revenue This Year
- OLP $11.08
- MLYS N/A
- Revenue Next Year
- OLP $4.64
- MLYS N/A
- P/E Ratio
- OLP $17.85
- MLYS N/A
- Revenue Growth
- OLP 7.07
- MLYS N/A
- 52 Week Low
- OLP $21.94
- MLYS $8.24
- 52 Week High
- OLP $30.45
- MLYS $39.20
- Technical
- Relative Strength Index (RSI)
- OLP 47.44
- MLYS 82.81
- Support Level
- OLP $22.75
- MLYS $34.59
- Resistance Level
- OLP $23.32
- MLYS $39.20
- Average True Range (ATR)
- OLP 0.41
- MLYS 2.83
- MACD
- OLP -0.04
- MLYS 0.73
- Stochastic Oscillator
- OLP 27.07
- MLYS 92.13
About OLP One Liberty Properties Inc.
One Liberty Properties Inc is a self-administered and self-managed real estate investment trust. It acquires, owns, and manages a geographically diversified portfolio consisting mainly of industrial and, to a lesser extent, retail properties, many of which are subject to long-term net leases. The trust has approximately one hundred two properties located across several states in the United States of America. A majority of its revenue is generated in the form of rental income.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.